Curis to Release 2005 First Quarter Financial Results and Hold Conference Call on April 26, 2005
Wednesday April 20, 8:30 am ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 20, 2005--Curis, Inc. (NASDAQ: CRIS - News), a therapeutic drug development company, will release its first quarter financial results on Tuesday, April 26, 2005 before the market opens. The Company will also hold a conference call to discuss the results, progress of its therapeutic product development programs, and additional corporate activities at 10:00 A.M. Eastern time. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.
To access the live conference call, please call 800-329-9097 from the United States or Canada or 617-614-4929 from other locations, shortly before 10:00 A.M. The conference ID number is 76295624. Replay will be available approximately two hours after the completion of the call and through 5:00 P.M. EST, Tuesday, May 10, 2005. To access the replay, please call 888-286-8010 from the United States or Canada or 617-801-6888 from other locations and reference the conference ID number 66419694.
About Curis, Inc.
Curis, Inc. is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. Curis' product development involves the use of proteins or small molecules to modulate these pathways. Curis has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer (under collaboration with Genentech, which also includes a co-development agreement between Curis and Genentech for a basal cell carcinoma product candidate), kidney disease (licensed to Ortho Biotech, a subsidiary of Johnson & Johnson), neurological disorders (in collaboration with Wyeth Pharmaceuticals), hair growth, and cardiovascular disease. For more information, please visit the Curis web site at www.curis.com. |
